RCT | Oral Paclitaxel plus Encequidar vs. intravenous Paclitaxel in patients with metastatic breast cancer.

Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer – Journal of Clinical Oncology

Commentary on Twitter

Oral Paclitaxel is an alternative treatment option to every 3-week paclitaxel with more neutropenic serious infections and less incidence and severity of neuropathy for patients with advanced or mBChttps://t.co/wNrLfs2myN pic.twitter.com/l3aWGhEdwU

— K Pavithran (@drkpavithran) July 21, 2022